Jaguar Animal Health, a biotech developing gastrointestinal treatments for companion and production animals, filed on Wednesday with the SEC to raise up to $70 million in an initial public offering. The company's lead drug candidate is for the treatment of watery diarrhea in dogs.
The San Francisco, CA-based company, which was founded in 2013, plans to list on the NASDAQ under the symbol JAGX. BMO Capital Markets and Guggenheim Securities are the joint bookrunners on the deal. No pricing terms were disclosed.
